Guangzhou Baiyunshan Pharmaceutical Holdings | Sustainability Performance
Researches, manufactures, and markets pharmaceutical products, traditional Chinese medicines, and healthcare items. Activities include product development, large-scale manufacturing, distribution to hospitals and pharmacies, and sales under multiple healthcare brands.
1997
China
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#1279
Overallⓘ#38
in Chinaⓘ#38
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementSocial
Diversity and Inclusion
Laggard
Laggard
Critical
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
13.9
B/M 22.4
40.9
B/M 42.0
Powered by illuminem and GIST Impact
Controversy level
- Guangzhou Baiyunshan Pharmaceutical Holdings, Chinese state-owned pharma, has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of multiple traditional Chinese medicine product quality and the contested historic 2018-2019 'Wang Lao Ji' herbal tea trademark dispute with Hong Kong's Hung To Group affecting Hong Kong-listed institutional shareholders.
